Elucidating the mechanism of regulation of transforming growth factor β type II receptor expression in human lung cancer cell lines

Neoplasia

Volumn 13, Issue 10, 2011, Pages 912-922

  Halder, Sunil K ^a   Cho, Yong Jig ^a,b   Datta, Arunima ^a   Anumanthan, Govindaraj ^a   Ham, Amy Joan L ^a   Carbone, David P ^a,c   Datta, Pran K ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 5 AZA 2' DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; ISOPROPYLTHIO BETA GALACTOSIDE; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR FACTOR Y; OLIGONUCLEOTIDE; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MEIS1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; BIOTINYLATION; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DEACETYLATION; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 80054829319     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11576     Document Type: Article

References (35)

1. Nagatake M, Takagi Y, Osada H, Uchida K, Mitsudomi T, Saji S, Shimokata K, Takahashi T, and Takahashi T (1996). Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 56, 2718-2720.
2. Uchida K, Nagatake M, Osada H, Yatabe Y, Kondo M, Mitsudomi T, Masuda A, Takahashi T, and Takahashi T (1996). Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res 56, 5583-5585.
3. Osada H, Tatematsu Y, Masuda A, Saito T, Sugiyama M, Yanagisawa K, and Takahashi T (2001). Heterogeneous transforming growth factor (TGF)-ß unresponsiveness and loss of TGF-ß receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res 61, 8331-8339.
4. Hougaard S, Norgaard P, Abrahamsen N, Moses HL, Spang-Thomsen M, and Skovgaard Poulsen H (1999). Inactivation of the transforming growth factor ß type II receptor in human small cell lung cancer cell lines. Br J Cancer 79, 1005-1011.
5. Anumanthan G, Halder SK, Osada H, Takahashi T, Massion PP, Carbone DP, and Datta PK (2005). Restoration of TGF-ß signalling reduces tumorigenicity in human lung cancer cells. Br J Cancer 93, 1157-1167.
6. Bae HW, Geiser AG, Kim DH, Chung MT, Burmester JK, Sporn MB, Roberts AB, and Kim SJ (1995). Characterization of the promoter region of the human transforming growth factor-ß type II receptor gene. J Biol Chem 270, 29460-29468.
7. Jennings R, Alsarraj M, Wright KL, and Munoz-Antonia T (2001). Regulation of the human transforming growth factor ß type II receptor gene promoter by novel Sp1 sites. Oncogene 20, 6899-6909.
8. Kelly D, Kim SJ, and Rizzino A (1998). Transcriptional activation of the type II transforming growth factor-ß receptor gene upon differentiation of embryonal carcinoma cells. J Biol Chem 273, 21115-21124.
9. Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG, Sorensen PH, Thiele CJ, and Kim SJ (1999). Repression of the gene encoding the TGF-ß type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 23, 222-227.
10. Johnstone RW (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1, 287-299.
11. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, and Kelly WK (2001). Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1, 194-202.
12. Vigushin DM and Coombes RC (2002). Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13, 1-13.
13. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, et al. (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7, 437-443.
14. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, and Nakanishi O (1999). A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96, 4592-4597.
15. Lee BI, Park SH, Kim JW, Sausville EA, Kim HT, Nakanishi O, Trepel JB, and Kim SJ (2001). MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor ß type II receptor expression in human breast cancer cells. Cancer Res 61, 931-934.
16. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE, and Thiele CJ (2002). MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 62, 6108-6115.
17. Halder SK, Beauchamp RD, and Datta PK (2005). Smad7 induces tumorigenicity by blocking TGF-ß-induced growth inhibition and apoptosis. Exp Cell Res 307, 231-246.
18. Halder SK, Beauchamp RD, and Datta PK (2005). A specific inhibitor of TGF-ß receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 7, 509-521.
19. Zhao S, Venkatasubbarao K, Li S, and Freeman JW (2003). Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor ß type II receptor expression in human pancreatic cancer cells. Cancer Res 63, 2624-2630.
20. Tabb DL, Fernando CG, and Chambers MC (2007). MyriMatch: highly accurate tandem mass spectral peptide identification by multivariate hypergeometric analysis. J Proteome Res 6, 654-661.
21. Zhang B, Chambers MC, and Tabb DL (2007). Proteomic parsimony through bipartite graph analysis improves accuracy and transparency. J Proteome Res 6, 3549-3557.
22. Ma ZQ, Dasari S, Chambers MC, Litton MD, Sobecki SM, Zimmerman LJ, Halvey PJ, Schilling B, Drake PM, Gibson BW, et al. (2009). IDPicker 2.0: improved protein assembly with high discrimination peptide identification filtering. J Proteome Res 8, 3872-3881.
23. Kim DH, Kim JS, Park JH, Lee SK, Ji YI, Kwon YM, Shim YM, Han J, and Park J (2003). Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. Cancer Res 63, 6206-6211.
24. Mukohara T, Kudoh S, Yamauchi S, Kimura T, Yoshimura N, Kanazawa H, Hirata K, Wanibuchi H, Fukushima S, Inoue K, et al. (2003). Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 41, 123-130.
25. Zhou X, Richon VM, Wang AH, Yang XJ, Rifkind RA, and Marks PA (2000). Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras. Proc Natl Acad Sci USA 97, 14329-14333.
26. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, et al. (2006). Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66, 944-950.
27. Knoepfler PS, Calvo KR, Chen H, Antonarakis SE, and Kamps MP (1997). Meis1 and pKnox1 bind DNA cooperatively with Pbx1 utilizing an interaction surface disrupted in oncoprotein E2a-Pbx1. Proc Natl Acad Sci USA 94, 14553-14558.
28. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, Wintersberger E, and Seiser C (1999). Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 19, 5504-5511.
29. Park SH, Lee SR, Kim BC, Cho EA, Patel SP, Kang HB, Sausville EA, Nakanishi O, Trepel JB, Lee BI, et al. (2002). Transcriptional regulation of the transforming growth factor ß type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. J Biol Chem 277, 5168-5174.
30. Huang W, Zhao S, Ammanamanchi S, Brattain M, Venkatasubbarao K, and Freeman JW (2005). Trichostatin A induces transforming growth factor ß type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex. J Biol Chem 280, 10047-10054.
31. Nagaraj NS and Datta PK (2010). Targeting the transforming growth factor-ß signaling pathway in human cancer. Expert Opin Investig Drugs 19, 77-91.
32. Yingling JM, Blanchard KL, and Sawyer JS (2004). Development of TGF-ß signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3, 1011-1022.
33. Siegel PM and Massague J (2003). Cytostatic and apoptotic actions of TGF-ß in homeostasis and cancer. Nat Rev Cancer 3, 807-821.
34. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, et al. (2002). Blockade of TGF-ß inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109, 1551-1559.
35. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, et al. (2002). Lifetime exposure to a soluble TGF-ß antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109, 1607-1615.